Amen Clinics
  • Amen Clinics
  • About
    • Our Difference
    • Our Method
    • Founder
    • Providers
    • Locations
      • Atlanta Metro Area
      • Chicago Metro Area
      • Dallas/Fort Worth Metro Area
      • Los Angeles Metro Area
      • Miami/Ft. Lauderdale Metro Area
      • New York Metro Area
      • Orange County Metro Area
      • Phoenix/Scottsdale Metro Area
      • San Francisco Bay Area
      • Seattle Metro Area
      • Washington D.C. Metro Area
    • Reviews
    • Services
    • Team
    • Pricing
  • Conditions
    • ADD/ADHD
    • Anxiety
    • Concussion
    • Depression
    • Memory Loss
    • PTSD
    • All Conditions
  • Learn
    • Brain SPECT Scans
    • Brain SPECT Research
    • Blog
    • Newsletter
    • Podcast
    • Ebooks
    • Infographics
    • Media & Press
    • Events & Conferences
  • Resources
    • Contact Us
    • Brain MD Supplements
    • Amen University Online Courses
    • Daniel Amen, MD
    • Tana Amen Nutrition & Wellness
    • Change Your Brain Foundation
    • Brain Warrior Alumni Network
  • For Providers
    • Partner With Us
    • Provider Support
    • Refer Your Patients
    • Referral Reviews
    • Provider Newsletter
949-427-8195

Predicting positive and negative treatment responses to stimulants with brain SPECT imaging.









rob | January 3, 2020

ABSTRACT:
The goal of this study was to test whether clinician-rated regional cerebral blood flow (rCBF) as rendered by SPECT imaging is a meaningful predictor of patient response to CNS stimulants. Chart reviews were used to identify patients who reported prior significant positive and negative responses to CNS stimulants. Each patient in the study had received resting and concentration SPECT scans using Tc99m exametazime. Differences in cerebral blood flow for frontal regions of interest were assessed in three conditions (resting, concentration, and their difference, or “delta”) using ANCOVAs and age-matched ANOVAs. Prefrontal pole deltas were found to be highly sensitive and specific predictors of response to CNS stimulants, with pole activation predicting adverse responses and pole deactivation predicting good responses. Positive and negative predictive values were greater than .75 for both poles. We conclude that SPECT renderings of rCBF, particularly in the prefrontal cortex, are a potentially powerful clinical tool for anticipating response to stimulant medications, both positive and adverse.

  • All Conditions
  • Brain SPECT Research
  • Brain SPECT Gallery
  • Peer-Reviewed Studies
  • FAQ
  • Blog
  • Careers
  • About Your Brain
  • Employee Owned

Got questions? Send us a message below or call us at 949-427-8195

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
This field is hidden when viewing the form
This field is hidden when viewing the form
Required Consent*
Optional Consent
  • Facebook
  • Instagram
  • TikTok
  • X
  • YouTube
  • LinkedIn

© 2026 Amen Clinics | Privacy Policy